De Novo KRAS G12C–Mutant SCLC: A Case Report

The application of KRAS G12C inhibitors in the setting of NSCLC represents a major milestone for a previously “undruggable” target. Here, we present the second reported case of de novo KRAS G12C–mutant primary SCLC. Would our patient benefit from a KRAS G12C inhibitor?

Detalles Bibliográficos
Autores principales: Balbach, Meridith L., Eisenberg, Rosana, Iams, Wade T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010630/
https://www.ncbi.nlm.nih.gov/pubmed/35434667
http://dx.doi.org/10.1016/j.jtocrr.2022.100306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010630/
https://www.ncbi.nlm.nih.gov/pubmed/35434667
http://dx.doi.org/10.1016/j.jtocrr.2022.100306

Ejemplares similares